Clinical trials: Urologic Surgery
Renal Cell Carcinoma
A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread
A medical review chart study in Japan to describe the treatment patterns and outcomes of patients with kidney cancer that is unable to be removed by surgery or that has spread.
- Trial name
- NCT03161145
- Where
- Japan
- Volunteers
- 297 people
- Sponsor
- Bristol-Myers Squibb
Acute Renal Failure, Acute Kidney Injury
A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)
This is a Phase 1, randomized, double-blind, dose escalation, safety and pharmacokinetic study. The study will be conducted in approximately 10 sites in the United States.
- Trial name
- NCT00683553
- Testing
- I5NP
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- Quark Pharmaceuticals
Kidney Cancer
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00087022
- Testing
- girentuximab
- Where
- 56 sites in United States, Argentina and 2 more
- Volunteers
- 864 people
- Sponsor
- Heidelberg Pharma AG
Nephrectomy
HYbrid RObotic Surgery in Urology
The HYbrid RObotic Surgery in urology (HYROS) study is an early feasibility clinical investigation of a new medical device under the commercial name of Bitrack System.
- Trial name
- HYROS (NCT05864040)
- Testing
- Bitrack System-assisted laparoscopic radical/simple nephrectomy
- Where
- Spain
- Volunteers
- 3 people
- Sponsor
- Rob Surgical Systems S.L.
Injury of Kidney, Acute Renal Failure
A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery
This is a Phase 1, randomized, double-blind, dose escalation, safety and pharmacokinetic study. The study will be conducted in approximately 8-10 centers in the United States and Switzerland.
- Trial name
- NCT00554359
- Testing
- I5NP (a small interfering RNA)
- Where
- 11 sites in United States, Israel and 1 more
- Volunteers
- 16 people
- Sponsor
- Quark Pharmaceuticals
Coronary Artery Bypass Surgery, Coronary Heart Disease
An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)
The purpose of this study is to assess whether nesiritide compared to placebo when given with standard of care therapies, helps preserve kidney function in heart failure (HF) patients undergoing heart bypass graft surgery that…
- Conditions
- Coronary Artery Bypass Surgery, Coronary Heart Disease, Coronary Artery Bypass Grafting, Cardiopulmonary Bypass
- Trial name
- NCT00530361
- Testing
- Nesiritide
- Sponsor
- Scios, Inc.
Renal Cell Cancer
A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)
This study will examine the effect of treatment with the neoadjuvant antibody pembrolizumab (MK-3475) on tumors of participants with renal cell cancer (RCC).
- Trial name
- NCT02212730
- Testing
- Pembrolizumab Pre-Resection, Surgical Resection, Pembrolizumab Post-Resection
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Kidney Injury, Cardiac Surgery
LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery
To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria: 1.
- Trial name
- NCT05879432
- Testing
- LSALT Peptide
- Where
- 9 sites in Canada, Turkey (Türkiye)
- Volunteers
- 240 people
- Sponsor
- Arch Biopartners Inc.
Acute Kidney Injury
Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery
This study evaluates RMC-035 compared to placebo for the prevention of acute kidney injury (AKI) in subjects who are at high risk for AKI following cardiac surgery.
- Trial name
- AKITA (NCT05126303)
- Testing
- RMC-035
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 177 people
- Sponsor
- Guard Therapeutics AB
Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult…
- Trial name
- NCT03661320
- Testing
- Nivolumab, Gemcitabine, Cisplatin
- Where
- 172 sites in United States, Argentina and 26 more
- Volunteers
- 855 people
- Sponsor
- Bristol-Myers Squibb
Stress Urinary Incontinence
Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
This study evaluates the efficacy and safety of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR; generic name: iltamiocel) compared to a placebo in the reduction of stress incontinence episode frequency in…
- Trial name
- CELLEBRATE (NCT03104517)
- Testing
- AMDC-USR (iltamiocel)
- Where
- 21 sites in United States, United Kingdom
- Volunteers
- 96 people
- Sponsor
- Cook MyoSite
AKI - Acute Kidney Injury, Cardiac Surgery Associated - Acute Kidney Injury
Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI
The goal of this clinical trial is to assess the effect of RenalGuard Therapy in reducing the rates of Acute Kidney Injury (AKI) within 72 hours after cardiac surgery in patients at risk of developing Cardiac Surgery Associated…
- Trial name
- KIDNEY-II (NCT06811805)
- Testing
- RenalGuard Therapy, Standard of Care (SOC)
- Where
- 8 sites in Belgium, Germany and 3 more
- Volunteers
- 300 people
- Sponsor
- CardioRenal Systems, Inc.
Elective Cardiac Surgery
CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery
Prospective, multi-center, randomized, blinded, pivotal clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care plus treatment with the CytoSorb® device.
- Trial name
- REFRESH II-AKI (NCT03384875)
- Testing
- CytoSorb
- Where
- 20 sites in United States
- Volunteers
- 186 people
- Sponsor
- CytoSorbents, Inc
Prostate Cancer, Kidney Cancer
DS Titanium Ligation Clip in Urology (Prostatectomy and Nephrectomy)
Prospective, monocentric, single arm, observational PMCF - Study on the Performance and Safety of Double-Shank Titanium Ligation Clip in Urology (Prostatectomy and Nephrectomy)
- Conditions
- Prostate Cancer, Kidney Cancer, Congenital Abnormality of Kidney, Nephrolithiasis
- Trial name
- DOSTILCU (NCT04869462)
- Where
- Germany
- Volunteers
- 67 people
- Sponsor
- Aesculap AG
Intraoperative Ureter Injury
Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery
The purpose of this clinical trial is to study the safety and efficacy of an investigational imaging agent for delineation/visualization of urologic anatomy in the setting of minimally invasive surgery.
- Trial name
- NCT03106038
- Testing
- Nerindocianine for Injection
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Li-Cor, Inc.
Acute Kidney Injury
Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass
The objective of the study is to assess the safety and efficacy of ANG-3777 in preventing AKI compared to placebo when administered to patients at risk for developing acute kidney injury (AKI) following cardiac surgical…
- Trial name
- NCT02771509
- Testing
- ANG-3777
- Where
- 40 sites in United States, Brazil and 2 more
- Volunteers
- 275 people
- Sponsor
- Angion Biomedica Corp
Surgery, Surgery in Early Childhood
The Asensus Paediatric Robotic Registry
An open-label, observational, paediatric registry trial in which participating centers enroll subjects who had or will have a laparoscopically-assisted surgery using the Senhance Surgical System.
- Trial name
- miniTRUST (NCT07081828)
- Testing
- Surgery
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Asensus Surgical
Renal Impairment After Cardiac Surgery, Renal Impairment
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
Patients with renal insufficiency who undergo cardiac surgery with cardiopulmonary bypass (CPB) are at significant risk for exacerbation of renal dysfunction postoperatively.
- Conditions
- Renal Impairment After Cardiac Surgery, Renal Impairment, Acute Kidney Injury
- Trial name
- GRADIENT (NCT07017933)
- Testing
- Renal assist device
- Where
- 7 sites in United States, Poland
- Volunteers
- 124 people
- Sponsor
- 3ive Labs
Bladder Cancer, Prostate Cancer
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
This study will evaluate the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures.
- Conditions
- Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor
- Trial name
- NCT05696444
- Testing
- RAS Prostatectomy, RAS Cystectomy, RAS Nephrectomy
- Where
- 6 sites in United States
- Volunteers
- 144 people
- Sponsor
- Medtronic - MITG
Acute Kidney Injury
Controlled Trial to Demonstrate a Reduction in the Number of Oliguria Events in Patients Being Managed in a Critical Care Unit, Following Cardiac Surgery, When a Novel Oliguria Prediction Tool (STABILITY UO) is Used to Identify Patients at Risk, Compared to Standard of Care.
Acute kidney injury (AKI) is experienced by 12% of patients following surgery and in up to 50% of patients following cardiac surgery.
- Trial name
- NCT05001503
- Testing
- Stability UO
- Where
- United Kingdom
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Rinicare Ltd